Pluristem Therapeutics, Inc. (PSTI): Price and Financial Metrics

Pluristem Therapeutics, Inc. (PSTI)

Today's Latest Price: $10.69 USD

0.02 (0.19%)

Updated Dec 4 11:33am

Add PSTI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

PSTI Stock Summary

  • The ratio of debt to operating expenses for Pluristem Therapeutics Inc is higher than it is for about just 7.88% of US stocks.
  • With a price/sales ratio of 11,702.2, Pluristem Therapeutics Inc has a higher such ratio than 99.8% of stocks in our set.
  • Revenue growth over the past 12 months for Pluristem Therapeutics Inc comes in at -54%, a number that bests just 4.41% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Pluristem Therapeutics Inc, a group of peers worth examining would be NK, AUPH, VTVT, PRKR, and CYAD.
  • Visit PSTI's SEC page to see the company's official filings. To visit the company's web site, go to

PSTI Stock Price Chart Interactive Chart >

Price chart for PSTI

PSTI Price/Volume Stats

Current price $10.69 52-week high $13.29
Prev. close $10.67 52-week low $2.82
Day low $10.55 Volume 107,435
Day high $10.88 Avg. volume 883,106
50-day MA $9.89 Dividend yield N/A
200-day MA $8.37 Market Cap 274.02M

Pluristem Therapeutics, Inc. (PSTI) Company Bio

Pluristem Therapeutics Inc. operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. The company was founded in 2001 and is based in Haifa, Israel.

PSTI Latest News Stream

Event/Time News Detail
Loading, please wait...

PSTI Latest Social Stream

Loading social stream, please wait...

View Full PSTI Social Stream

Latest PSTI News From Around the Web

Below are the latest news stories about Pluristem Therapeutics Inc that investors may wish to consider to help them evaluate PSTI as an investment opportunity.

Pluristem Therapeutics up on insider buy

Clover Wolf Capital who owns more than 10% of Pluristem Therapeutics (PSTI) bought additional 199,219 common shares for transaction value of $2M.Shares are up 1.8% in premarket....

Seeking Alpha | October 2, 2020

Pluristem launches COVID-19 expanded access program

The FDA has cleared Pluristem Therapeutics' (PSTI) Expanded Access Program ((EAP)) for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome ((ARDS)) caused by COVID-19 outside of the Company’s Phase II COVID-19 study in the U.S.The program provides a pathway for patients that were included in the ongoing...

Seeking Alpha | August 27, 2020

Pluristem CEO Issues Shareholder Update on Clinical Programs

HAIFA, Israel, July 21, 2020 -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological.

Yahoo | July 21, 2020

Pluristem Is a High Risk, High Reward Play, Says Jefferies Analyst

Just how high can Pluristem Therapeutics (PSTI) climb? The Israeli biotech has outperformed in 2020, with shares up by 94% year-to-date. Driving the micro-cap’s forward charge has been a familiar 2020 narrative. The company’s PLX-PAD cell therapy, which uses allogeneic mesenchymal-like cells with immunomodulatory properties, has shown promising early results as a possible treatment for COVID-19.However, Jefferies analyst Chris Howerton’s bullish thesis for PSTI rests on the PLX-PAD program’s potential as a therapy for an entirely different indication.“PLX-PAD could be the first approved therapeutic in critical limb ischemia (CLI), which has massive unmet need (~2 million-plus US patients; $1 billion-plus potential, peak unadjusted sales),” Howerton said.Critical limb ischemia occurs whe...

Yahoo | June 24, 2020

Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial

Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today the activation of clinical sites and initiation of enrollment in its Phase II U.S. Food and Drug Administration (FDA) study of PLX cells for the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS). The Company is focused on expanding to clinical sites throughout the U.S. in accordance with the changing dynamic spread of the COVID-19 pandemic, using its advanced operational capabilities and cold chain agility.

Yahoo | June 11, 2020

Read More 'PSTI' Stories Here

PSTI Price Returns

1-mo 9.08%
3-mo 8.20%
6-mo 38.47%
1-year 182.80%
3-year -25.24%
5-year -31.03%
YTD 171.32%
2019 -50.13%
2018 -42.75%
2017 -3.50%
2016 26.55%
2015 -54.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8875 seconds.